CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← RedHill Biopharma Ltd. (RDHL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

RedHill Biopharma Ltd. (RDHL)

Pharmaceutical Preparations · market cap $2M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
RedHill Biopharma Ltd. (RDHL) is a small pharmaceutical company with 35 employees and a market cap of approximately $41.4 million, trading at roughly $0.71 per share. The company operates a multi-asset pipeline spanning Phase 2 and Phase 3 trials across infectious disease, gastrointestinal conditions, and oncology, with opaganib as its lead asset in a Phase 3 COVID-19 trial. Critical financial data — including cash position, runway, and dilution history — is unavailable, creating significant opacity around the company's near-term viability.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
ABC294640Phase 2Cholangiocarcinoma
OpaganibPhase 3COVID-19
RHB-105Phase 3Helicobacter Pylori Infection
RHB-102Phase 3Gastroenteritis
BEKINDAPhase 2Irritable Bowel Syndrome With Diarrhea
RHB-104Phase 3Crohn's Disease
RHB-104 (fixed-dose combination: clarithromycin, rifabutin, and clofazimine)Phase 3Crohn Disease
UpamostatPhase 2SARS-CoV-2
Hydroxychloroquine SulfatePhase 2Cholangiocarcinoma
Price & technical context
3-month
-49.2%
6-month
-66.0%
12-month
-69.8%
52-wk range
$0.32–$1.40
vs 50-day MA
-32.1%
vs 200-day MA
-57.3%
Realized vol
88.2%
Max drawdown
-96.2%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for RDHL (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.